Hosted by: Diagnostic Solutions Laboratory
GLP-1 receptor agonists have transformed the treatment of obesity and type 2 diabetes, but their effects extend far beyond weight loss. As more patients begin GLP-1 therapy, healthcare practitioners are increasingly encountering gastrointestinal symptoms, changes in bowel habits, altered digestion, and questions about how these medications influence the gut microbiome and overall gastrointestinal function.
Join Dr. Daniel Kalish as he explores the relationship between GLP-1 medications and gut health through a functional medicine lens. This webinar will discuss how
comprehensive stool testing with GI-MAP® and metabolomic assessment with StoolOMX™ can provide valuable clinical insights into the gastrointestinal ecosystem,
including microbial balance, digestive function, inflammation, bile acid metabolism, and short-chain fatty acid production.
Learn how these complementary tests can help you better understand gastrointestinal changes in patients taking GLP-1 medications, identify potential contributors to persistent digestive symptoms, and support more personalized treatment strategies.
References to webinars are from our accredited laboratory network. Health care providers are encouraged to explore the original source material and apply their clinical expertise when interpreting this information.